Since the approval of vorinostat for the treatment of refractory cutaneous epidermotropic T-cell lymphoma (CTCL) in 2006, very little data about this treatment have been published. The aim of this retrospective study was to assess the efficacy and safety of vorinostat in patients with CTCL treated between 2007 and 2013 in our department. Fifteen patients (median age 64 years) were included: 9 with Sézary syndrome and 6 with mycosis fungoides. They were all in progression and the median number of systemic treatments previously administered was 3 (range 1-7). With vorinostat treatment, the best response was partial remission in 5 patients (33

作者：Anne, Kogge；Christelle, Volteau；Mélanie, Saint-Jean；Lucie, Peuvrel；Anabelle, Brocard；Anne-Chantal, Knol；Jean-Jaques, Renaut；Brigitte, Dréno；Ga?lle, Quéreux

来源：Acta dermato-venereologica 2015 年 95卷 1期